Leap Investments’s Coherus Oncology CHRS Stock Holding History

Leap Investments’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-26,100	Closed	-$423K	–	421
2020 Q1	$423K	Buy	+26,100	New	+$482K	0.62%	17

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Leap Investments's CHRS Position: Q2 2020 in Review

Leap Investments sold out of Coherus Oncology (CHRS) in Q2 2020, closing a stake of 26,100 shares — an estimated $423K sold.

Leap Investments first reported a position in CHRS in Q1 2020 and held it in 1 quarter. The position peaked at $423K in Q1 2020. 188 funds tracked by Wall St. Rank hold CHRS as of Q2 2020.

Leap Investments reported no remaining Coherus Oncology position as of Q2 2020 after selling out during the quarter.
Leap Investments sold 26,100 Coherus Oncology shares in Q2 2020, an estimated $423K.
Leap Investments first reported a position in Coherus Oncology in Q1 2020 and held it in 1 quarter.
Leap Investments's Coherus Oncology position peaked at $423K in Q1 2020.
188 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2020.

Based on Leap Investments's 13F filing for Q2 2020, filed 3 Aug 2020.